ThinPrep Pap Test
The ThinPrep Pap Test is the most widely used method for cervical cancer screening in the United States. It was developed to address the limitations of the conventional Pap smear. The ThinPrep Pap Test was approved in May 1996 by the U.S. Food and Drug Administration (FDA) after rigorous clinical trials, as a replacement for the conventional Pap smear.
Since FDA approval, many studies have been published, in peer-reviewed medical journals, demonstrating a wide range of clinical benefits of the ThinPrep Pap Test including increased disease detection, reduction of ASCUS diagnoses, improved specimen adequacy, cost effectiveness and the ability to perform human papillomavirus (HPV) testing out of the same vial.
The ThinPrep Pap Test is the only replacement to the conventional Pap smear that has Food & Drug Administration (FDA) labeling claims stating that the ThinPrep is significantly more effective than the conventional Pap smear for the detection of low-grade squamous intraepithelial (LSIL) and more severe lesions in a variety of patient populations.
The Thin Prep Pap test is very easy to implement in your practice. Patient samples are collected the same as with a conventional Pap smear; however, the collection device is rinsed into a vial of preservative solution instead of being smeared on a slide. At the laboratory, the ThinPrep process disperses and filters the sample to produce a more representative patient sample with less obscuring material.